KRSA · Korsana Biosciences, Inc.
$31.55
+0.83 (+2.70%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Market Cap
$20.73M
Shares
668,764
Volume · Oct 6
7130
Avg daily vol (19 sessions)
76.23K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$30.72
Open$30.49
Day$29.93–31.66
52W close$7.56–44.66
Avg vol 30d55K
Short int4K · 0.7% float · 1.0d
Short vol44%
Last earningsApr 1, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 4
Up next
filed Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.7%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+54%
above
Price vs 50-day avg
+7%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
62%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+3%
trailing
6-month return
+36%
trailing
YTD return
+246%
this year
Relative strength
+25%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $29 › 200d $20 — 50d above 200d
Institutional flow
Accumulating
+24% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.66% of float · ▲ +72.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
21 holders — near 3-yr high, broad support
Squeeze score
46
elevated · 0–100
Fundamentals
Revenue growth
+4%
Y/Y
EPS growth
+8%
Y/Y
Free cash flow
$-3.3M
Quant / Vol
risk profile
Volatility
328%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
12.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+54%
Bullish
Price vs 50-day avg
+7%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
62%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $29 › 200d $20 — 50d above 200d
Institutional flow
Accumulating
+24% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.66% of float · ▲ +72.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
21 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $8
Now $31 · 62%
Range high $45
vs 200-day avg +54%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KRSA
this stock
Korsana Biosciences, Inc.
|
$20.73M | — | +3.7% | — | 0.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KRSA | -0.4% | +3.3% | +36.3% | -4.0% | +245.6% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -1.6% | +2.7% | +24.7% | -5.6% | +231.9% |